- Home
- EVOK vs JZ Comparison
EVOK vs JZ Comparison
Compare EVOK & JZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- JZ
- Stock Information
- Founded
- EVOK 2007
- JZ 2011
- Country
- EVOK United States
- JZ China
- Employees
- EVOK 3
- JZ N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- JZ Other Consumer Services
- Sector
- EVOK Health Care
- JZ Real Estate
- Exchange
- EVOK Nasdaq
- JZ Nasdaq
- Market Cap
- EVOK 7.6M
- JZ 4.9M
- IPO Year
- EVOK 2013
- JZ 2022
- Fundamental
- Price
- EVOK $4.90
- JZ $1.67
- Analyst Decision
- EVOK
- JZ
- Analyst Count
- EVOK 0
- JZ 0
- Target Price
- EVOK N/A
- JZ N/A
- AVG Volume (30 Days)
- EVOK 27.4K
- JZ 7.3K
- Earning Date
- EVOK 11-07-2025
- JZ 10-16-2025
- Dividend Yield
- EVOK N/A
- JZ N/A
- EPS Growth
- EVOK N/A
- JZ N/A
- EPS
- EVOK N/A
- JZ N/A
- Revenue
- EVOK $12,794,859.00
- JZ $34,090,704.00
- Revenue This Year
- EVOK $57.38
- JZ N/A
- Revenue Next Year
- EVOK $59.57
- JZ N/A
- P/E Ratio
- EVOK N/A
- JZ N/A
- Revenue Growth
- EVOK 70.02
- JZ N/A
- 52 Week Low
- EVOK $1.94
- JZ $1.30
- 52 Week High
- EVOK $12.32
- JZ $14.60
- Technical
- Relative Strength Index (RSI)
- EVOK 52.02
- JZ 49.27
- Support Level
- EVOK $4.53
- JZ $1.64
- Resistance Level
- EVOK $4.69
- JZ $1.88
- Average True Range (ATR)
- EVOK 0.27
- JZ 0.10
- MACD
- EVOK 0.06
- JZ 0.01
- Stochastic Oscillator
- EVOK 61.43
- JZ 43.23
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About JZ Jianzhi Education Technology Group Company Limited
Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has two operating segments: Educational content services and other services and IT-related solution services.